BENRALIZUMAB- Emerging Insight and Market Forecast - 2030
発行: DelveInsight Business Research LLP
ページ情報: 英文 60 Pages
当レポートでは、新しい慢性特発性蕁麻疹治療薬であるBENRALIZUMABの主要7カ国 (米国・ドイツ・フランス・イタリア・スペイン・英国・日本) における展望を調査し、製品概要、作用機序、臨床開発・臨床試験の動向、関連法規制、特許動向、売上予測、競合状況、SWOT分析、アナリストの見解などをまとめています。
"BENRALIZUMAB- Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Chronic Spontaneous Urticaria in 7 Major Markets. A detailed picture of the BENRALIZUMAB in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
Fasenra is a monoclonal antibody that binds directly to IL-5 receptor alpha on eosinophils and attracts natural killer cells to induce rapid and near-complete depletion of eosinophils via apoptosis (programmed cell death). Fasenra is AstraZeneca's first respiratory biologic, now approved as an add-on maintenance treatment for severe eosinophilic asthma in the US, EU, Japan and other countries, with further regulatory reviews ongoing. In the US, Fasenra is approved for self-administration in the Fasenra Pen. In the EU, Fasenra is approved for self-administration in either the single-use, pre-filled syringe or the Fasenra Pen. Fasenra was developed by AstraZeneca and is in-licensed from BioWa, Inc., a wholly-owned subsidiary of Kyowa Kirin Co., Ltd., Japan.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
BENRALIZUMAB Analytical Perspective by DelveInsight
This report provides a detailed market assessment of BENRALIZUMAB in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.
The report provides the clinical trials information of BENRALIZUMAB covering trial interventions, trial conditions, trial status, start and completion dates.